- Home
- ATYR vs AUDC Comparison
ATYR vs AUDC Comparison
Compare ATYR & AUDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATYR
- AUDC
- Stock Information
- Founded
- ATYR 2005
- AUDC 1992
- Country
- ATYR United States
- AUDC Israel
- Employees
- ATYR N/A
- AUDC N/A
- Industry
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- AUDC Telecommunications Equipment
- Sector
- ATYR Health Care
- AUDC Utilities
- Exchange
- ATYR Nasdaq
- AUDC Nasdaq
- Market Cap
- ATYR 327.0M
- AUDC 299.7M
- IPO Year
- ATYR 2015
- AUDC 1999
- Fundamental
- Price
- ATYR $3.54
- AUDC $10.04
- Analyst Decision
- ATYR Strong Buy
- AUDC Buy
- Analyst Count
- ATYR 6
- AUDC 2
- Target Price
- ATYR $18.60
- AUDC $11.25
- AVG Volume (30 Days)
- ATYR 1.8M
- AUDC 73.6K
- Earning Date
- ATYR 03-13-2025
- AUDC 05-06-2025
- Dividend Yield
- ATYR N/A
- AUDC 1.82%
- EPS Growth
- ATYR N/A
- AUDC 78.82
- EPS
- ATYR N/A
- AUDC 0.50
- Revenue
- ATYR $235,000.00
- AUDC $242,176,000.00
- Revenue This Year
- ATYR $1,387.23
- AUDC $5.11
- Revenue Next Year
- ATYR $873.22
- AUDC $3.79
- P/E Ratio
- ATYR N/A
- AUDC $19.78
- Revenue Growth
- ATYR N/A
- AUDC N/A
- 52 Week Low
- ATYR $1.42
- AUDC $7.70
- 52 Week High
- ATYR $4.66
- AUDC $13.71
- Technical
- Relative Strength Index (RSI)
- ATYR 49.19
- AUDC 39.36
- Support Level
- ATYR $3.63
- AUDC $9.85
- Resistance Level
- ATYR $3.94
- AUDC $10.69
- Average True Range (ATR)
- ATYR 0.33
- AUDC 0.27
- MACD
- ATYR 0.01
- AUDC -0.04
- Stochastic Oscillator
- ATYR 50.53
- AUDC 23.23
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
About AUDC AudioCodes Ltd.
AudioCodes Ltd develops and sells advanced and converged voice over IP and data networking solutions, products and applications to service providers and channels, OEMs, network equipment providers and system integrators. Its products include IP phones, session border controllers, voice applications, multi-service business routers, digital and analog media gateways, among others. The company generates revenues from the sale of products through a direct sales force and sales representatives. Its geographic segments are Israel, Americas, Europe, and the Far East. It derives a majority of the revenues from Americas segment.